Nexium Control overview
The UK’s No 1 for 24-hour heartburn protection1
Unlike antacids and alginates that treat the symptoms of heartburn, Nexium Control tackles the cause by targeting acid directly at the source providing long-lasting protection.
For news, updates and access to more resources please register now to be on our mailing list.
Nexium Control – Clinically proven protection for frequent heartburn
Long lasting protection
With just one pill a day Nexium Control provides up to 24 hour protection for frequent heartburn sufferers.
8 out of 10 people reported first resolution within the first week of treatment with Nexium Control.
4 out of 5 nights were heartburn free for patients using Nexium Control..
Nexium Control – Your first line recommendation for frequent heartburn
A key question for heartburn sufferers
Suffering twice or more per week with heartburn is classed as frequent heartburn.
Regardless of its severity, frequent heartburn makes the oesophagus sensitive to acid such that it does not take a lot to trigger burning pain
Ask your patients ‘How often do you suffer from heartburn each week?’
Learn more about how the frequency of heartburn may impact treatment recommendations by clicking here.
Break the cycle of short-term heartburn relief with Nexium Control
Nexium Control is a proton pump inhibitor (PPI) containing 20mg esomeprazole.
It works by reducing the production of acid in the stomach, providing up to 24 hour protection from heartburn.
Antacids and alginates offer short term relief from the pain of occasional heartburn until the stomach empties. At this point more acid is produced and the cycle starts again.
Nexium Control can break the cycle of short-term relief by reducing the production of stomach acid up to 24-hours. It treats the cause and symptoms of heartburn, allowing time for the oesophagus to recover from the acid irritation.
Duration of treatment Mode of action Antacids 1-3 hours Neutralises acid content in stomach. Repeated dosing necessary for newly secreted acid. Alginates Up to 4 hours Forms a raft on top of stomach contents to prevent escape through sphincter. Repeated dosing necessary for newly secreted acid. H2 blockers Up to 12 hours Blocks one of the 3 signals that stimulate acid production. Intermediate duration relief. PPI’s e.g. esomeprazole Up to 24 hours Acts on proton pump to reduce acid production. The lack of acid leaking from the stomach gives the oesophagus a ‘holiday’ from acid.
Nexium Control helps restore frequent heartburn sufferers’ quality of life
Frequent heartburn can cause significant disruption to people’s lives, forcing them to avoid certain foods or making it difficult to get a good night’s sleep.
Research has shown that within just 2 weeks of treatment with esomeprazole, the active ingredient in Nexium Control, the impact on quality of life by heartburn can be significantly improved or normalised.
Improvements in scores were observed in nearly every quality-of-life parameter measured, including:2
- Social functioning
- Activities affected by emotional or physical health
NICE guidelines recommend PPI’s, such as Nexium Control, as first line treatment for frequent heartburn3
Find out more about the impact of frequent heartburn in this video featuring a patient who also shares how Nexium Control has helped to provide him with relief.
Recommend Nexium Control for your patients with frequent heartburn
Nexium Control 20mg Gastro-Resistant Tablets (Esomeprazole)
Up to 24 hour relief and protection from frequent heartburn with just one pill a day.
Available in pack sizes of 7 and 14 tablets.
Nexium Control 20mg Gastro-Resistant Capsules (Esomeprazole)
Up to 24 hour relief and protection from frequent heartburn with just one pill a day.
Easy to swallow mini capsules: 53% smaller than tablets.*
Available in pack size of 14.
*based on volume of tablets vs. capsules
Nexium Control 20 mg gastro‑resistant tablets and hard capsules. Esomeprazole. Indications: The short‑term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg esomeprazole (one tablet or capsule) per day. It might be necessary to take the tablets or capsules for 2‑3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Warnings and precautions: Patients should be instructed to consult a doctor if: They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis. They have had previous gastric ulcer or gastrointestinal surgery. They have been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks. They have jaundice or severe liver disease. They are aged over 55 years with new or recently changed symptoms. Patients with long‑term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Patients over 55 years taking any non‑prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor. Patients should not take Nexium Control as a long term preventive medicinal product. Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile. Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test. Co‑administration of esomeprazole with atazanavir is not recommended. If the combination of atazanavir with a PPI is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir. Esomeprazole 20 mg should not be exceeded. Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with medicinal products metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole although the clinical relevance of this interaction is uncertain. The use of esomeprazole with clopidogrel should be discouraged. Patients should not take another PPI or H2 antagonist concomitantly. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of PPI treatment. Proton pump inhibitors are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Nexium Control. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors. This medicinal product contains sugar spheres (sucrose). Patients with rare hereditary problems of fructose intolerance, glucose‑galactose malabsorption or sucrase‑isomaltase insufficiency should not take this medicinal product. Side effects: See SPC for full details. Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash urticaria. Rare: leukopenia, thrombocytopenia, hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock, hyponatraemia, agitation, confusion, depression, taste disturbance, blurred vision, bronchospasm, stomatitis, gastrointestinal candidiasis, hepatitis with or without jaundice, alopecia, photosensitivity, arthralgia, myalgia, malaise, increased sweating. Very rare: agranulocytosis, pancytopenia, aggression, hallucinations, hepatic failure, hepatic encephalopathy in patients with pre-existing liver disease, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), muscular weakness, interstitial nephritis, gynaecomastia. Not known: hypomagnesaemia; severe hypomagnesaemia can correlate with hypocalcaemia; hypomagnesaemia may also result in hypokalaemia, microscopic colitis, subacute cutaneous lupus erythematosus SCLE. Legal category: GSL. Product licence number: PLGB 44673/0221 and PLGB 44673/0222. MAH: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, Brentford, TW8 9GS RRP: Pack of 7 tablets RRP £6.99, pack of 14 tablets RRP £11.99. Pack of 14 capsules RRP £12.99. The prices include VAT. Text prepared: January 2021